Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the immunotherapy desk.
health
In the phase 2 UNICORN trial, botensilimab plus balstilimab produced major pathological responses in 36% of pMMR and 100% of dMMR colon cancer cohorts before surgery. The small, non-randomized study provides an early clinical signal rather than a treatment comparison.
health
A BMJ clinical review describes how molecular classification, kidney-sparing treatment and immune-based combinations are shaping renal cell carcinoma care. It highlights improved outcomes in some settings alongside persistent resistance and a lack of validated biomarkers to guide treatment choice.
health
A prespecified five-year analysis of RELATIVITY-047 found lower hazards of progression and death with relatlimab plus nivolumab than with nivolumab alone. Exploratory biomarker analyses also linked higher LAG-3-positive CD8 cell levels to worse outcomes on nivolumab in a defined subgroup.
health
In the 31-patient exploratory GDFATHER-NEO trial, nivolumab plus visugromab was associated with higher pathological and radiographic response rates than nivolumab plus placebo before bladder surgery. The small, nonrandomized study was not designed to establish long-term benefit.
health
A bioRxiv preprint describes CIDER, a whole-genome sequencing score based on reconstructed T-cell receptor sequences. In patient cohorts, higher scores were associated with better outcomes among people treated with immune checkpoint inhibitors.
science
A bioRxiv preprint describes three recurring leukaemia stem-cell states in paediatric acute myeloid leukaemia and reports that the surface antigens CLEC12A and CD84 together cover them broadly. The findings offer a target-selection framework for future immunotherapy research.
health
An analysis of 783 patients with lymphoma linked a higher proportion of naive-like T cells in CAR T products to longer progression-free survival. The association was also found in an independent validation cohort.
health
A bioRxiv preprint describes NeoOmni Atlas, a database built by reanalysing mass-spectrometry data from 26 cancer types. It catalogues HLA-presented peptides and computationally prioritises potential tumour-associated and tumour-specific targets.
health
A phase 1 trial tested a personalized neoantigen vaccine after platinum chemotherapy in people with high-grade epithelial ovarian cancer. The researchers reported biological activity signals in six of 10 vaccinated patients, alongside immune responses in blood and tumour.
health
A pooled analysis of 1,038 patients found 86.5% five-year overall survival after neoadjuvant immune checkpoint inhibitors for resectable melanoma. Among patients whose tumours had a major pathological response, estimated five-year survival was 98%.
health
A bioRxiv preprint reports that an early interferon-responsive neutrophil program tracked resistance to anti-PD-1 therapy in preclinical models of triple-negative breast cancer. Genetic disruption of interferon signalling in neutrophils improved treatment responses in those models.
health
A bioRxiv preprint links CXCR6-positive tissue-resident CD4 memory T cells with response to immune checkpoint inhibition in a glioma model. Analysis of patient tumour tissue also found an association with longer overall survival.
health
A bioRxiv preprint reports that engineered Salmonella strain AD51, combined with intratumoral IFNγ, reduced tumour burden in mouse ovarian cancer and melanoma models. The findings are preclinical.
health
A bioRxiv preprint reports that harmine plus exendin-4, given after low-dose anti-CD3 therapy, promoted remission in diabetic mice. Human cell experiments also showed effects on beta-cell function and immune responses.
health
A South Korean phase 1b/2 trial found a 55% objective response rate when trastuzumab and nivolumab were added to gemcitabine and cisplatin for previously untreated HER2-positive advanced biliary tract cancer. The single-arm results provide early evidence for first-line HER2-targeted chemoimmunotherapy, while randomized confirmation is still needed.
health
A bioRxiv preprint describes IL-2IT, a bispecific fusion protein designed to carry IL-2 to oxidation-specific epitopes at inflamed sites. In laboratory and in vivo models, the treatment showed greater Treg selectivity and benefits in psoriasis, colitis and atherosclerosis models.
health
A retrospective study of 2,396 people with advanced NSCLC found clinical-data AI models outperformed single biomarkers and helped physicians predict treatment response and survival.